Key Highlights

Nascent Pharma Holdings (Can-B-Corp. | OTC: CANB)
Nascent Pharma is a forward-thinking pharmaceutical Intellectual Property (IP) company, focused on maximizing the value of our cannabis patent portfolios.

Our Patents:

We own two issued patents covering cannabis extracts and methods of preparation, emphasizing both composition and use.

Strategic Monetization:

Leveraging our intellectual property in the rapidly growing cannabis industry with global expansion and collaboration opportunities.

Our Vision:

To continue pioneering cannabis industry research to unlock growth potential in a dynamic sector.

Key Highlights

We own two issued patents registered with the US Patent and Trademark Office (USPTO) covering cannabis extracts and methods of preparation, emphasizing both composition and use.

Assignment details for assignee NASCENT PHARMA LLC
Download Document

911 Patent (US 9,730,911 B2) | “Novel Cannabinoid Formulation for Pain Management”

This groundbreaking patent covers unique cannabinoid formulations. Nascent Pharma holds exclusive rights to this innovative solution, positioning us as pioneers in cannabinoid-based pain relief.

Groundbreaking patent covers liquid formulations of cannabis where the present cannabinoids meet or exceed 95% purity.

Cannabinoids include CBD, THC, CBN, CBDa, THCa, or various combinations.

Applicable to beverages, tinctures, vape pen liquids, oils, gummies liquid-filled capsules and other non-flower products.

Significantly impacts the hemp and cannabis industry (potentially up to 50%).

Granted in 2017

Effective until 2035

Download Document

928 Patent (US 10,555,928 B2) | “Methods of Treating Neurological Disorders Using Cannabidiol Derivatives”

Nascent Pharma’s patented methods harness the therapeutic potential of cannabidiol derivatives.

These cutting-edge approaches are specifically tailored to address various neurological disorders, offering hope and improved quality of life for patients.

Nascent Pharma’s patented methods harness the therapeutic potential of cannabidiol derivatives.

These cutting-edge approaches are specifically tailored to address various neurological disorders, offering hope and improved quality of life for patients.

Download Document

Patent Validity for 911 Patent (US 9,730,911 B2) and 928 Patent (US 10,555,928 B2)

Valid in the United States

Valid in multiple countries: Canada, New Zealand, Israel, Brazil

Pending in the European Union, India, China, Eurasia, South Korea, Mexico, Japan, Australia, and Colombia

Effective until 2035

Licensing Agreements via Infringement Pursuits

We will establish new partnerships with cannabis manufacturers and leverage our patented technologies.

The licensing agreements are estimated at a 10% royalty rate on gross revenues, providing a steady stream of revenue.

Sales and Royalties

By commercializing our cannabis-based technologies, we expect to generate sales revenue and collect royalties at approximately 10% of gross revenues from sales.

The company is actively exploring new distribution channels to reach more patients and healthcare providers.

High Potency Cannabinoid Liquid Formulation

Produces a high potency liquid formulation of cannabinoids, including THC, THCa, CBD, CBDa, CBN and other minor cannabinoids.

We aim to establish new partnerships with the top 35 public companies with annual aggregate revenue in excess of $9 billion, providing our company a substantial market opportunity.

We have Identified 55% of the aggregate $9 billion or approximately $4.95 billion as immediate opportunity with this number predicted to increase year over year.

We have also identified commercial potential revenue stream for the patents.

Nascent Pharma’s commitment to innovation, strategic partnerships, and patient well-being sets it apart in the cannabis patent landscape. As the company continues to unlock value from its patents, investors and stakeholders can expect the potential of promising returns.

Industry Growth Drivers:

Favorable outlook on existing and future Government regulations

Increasing acceptance of cannabis-based treatments

Nascent Pharma’s Strategic Positioning:

Capitalizing on industry trends

Innovation-focused approach

Strong strategic partnerships

Commitment to Patient Well-being:

Prioritizing patient care in product development

Our Commitment to the Future:

To leverage our intellectual property in the rapidly growing health and wellness industry with global expansion and collaboration opportunities.